NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Epicrispr Biotechnologies

Epicrispr Biotechnologies

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://epicrispr.com/

Last Round

Series B

Mar 26, 2025

Est. Valuation

$95.14M

Total Funding Raised

$123M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Epicrispr Biotechnologies is a biotechnology company developing gene-modulating therapies using its proprietary Gene Expression Modulation System (GEMS) to treat a range of genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

epigenetic engineeringepigenetic editinggene expression modulationgenetic medicinesCRISPR-based platformCRISPR 2.0gene therapyepigenome editingFSHD therapyrare disease therapygene silencingAAV vector deliveryGEMS platformCasMINIneuromuscular disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Epicrispr Biotechnologies Comps

Public and private peers based on sector, stage, and business model.

Epicrispr Biotechnologies comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Epicrispr Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 26, 2025
Series AJul 12, 2022

Key People

Founding team and executive leadership

Amber Salzman

CEO, CEO

Executive Team

Epicrispr Biotechnologies Investors

Notable investors and investment history

Epicrispr Biotechnologies investors
InvestorRounds
Horizons VenturesSeries A
Ally Bridge GroupSeries B
Solve FSHDSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 24, 2026

    Named to Fast Company's Most Innovative Companies list.

  • Dec 8, 2025

    Will present at the 44th Annual J.P. Morgan Healthcare Conference.

Epicrispr Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Epicrispr Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Epicrispr Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range44
Year Founded2018
Last FundingMar 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.